Works matching IS 11707690 AND DT 2023 AND VI 41 AND IP 12

Results: 9

The Carer QALY Trap and Altruism in Economic Evaluations.

Published in:

PharmacoEconomics, 2023, v. 41, n. 12, p. 1553, doi. 10.1007/s40273-023-01324-0

By:

Tilford, J. Mick;
Tarlan, Aygul

Publication type:

Article

Handling Missing Data in Health Economics and Outcomes Research (HEOR): A Systematic Review and Practical Recommendations.

Published in:

PharmacoEconomics, 2023, v. 41, n. 12, p. 1589, doi. 10.1007/s40273-023-01297-0

By:

Mukherjee, Kumar;
Gunsoy, Necdet B.;
Kristy, Rita M.;
Cappelleri, Joseph C.;
Roydhouse, Jessica;
Stephenson, Judith J.;
Vanness, David J.;
Ramachandran, Sujith;
Onwudiwe, Nneka C.;
Pentakota, Sri Ram;
Karcher, Helene;
Di Tanna, Gian Luca

Publication type:

Article

Cost-Effectiveness of Hydroxyurea for Sickle Cell Anemia in a Low-Income African Setting: A Model-Based Evaluation of Two Dosing Regimens.

Published in:

PharmacoEconomics, 2023, v. 41, n. 12, p. 1603, doi. 10.1007/s40273-023-01294-3

By:

Teigen, David;
Opoka, Robert O.;
Kasirye, Phillip;
Nabaggala, Catherine;
Hume, Heather A.;
Blomberg, Bjørn;
John, Chandy C.;
Ware, Russell E.;
Robberstad, Bjarne

Publication type:

Article

Modelling Spillover Effects on Informal Carers: The Carer QALY Trap.

Published in:

PharmacoEconomics, 2023, v. 41, n. 12, p. 1557, doi. 10.1007/s40273-023-01316-0

By:

Mott, David J.;
Schirrmacher, Hannah;
Al-Janabi, Hareth;
Guest, Sophie;
Pennington, Becky;
Scheuer, Nicolas;
Shah, Koonal K.;
Skedgel, Chris

Publication type:

Article

Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzerland.

Published in:

PharmacoEconomics, 2023, v. 41, n. 12, p. 1641, doi. 10.1007/s40273-023-01305-3

By:

Barbier, Michaela Carla;
Fengler, Alicia;
Pardo, Esther;
Bhadhuri, Arjun;
Meier, Niklaus;
Gautschi, Oliver

Publication type:

Article

Estimating the Potential Benefits of Confirmatory Trials for Drugs with Accelerated Approval: A Comprehensive Value of Information Framework.

Published in:

PharmacoEconomics, 2023, v. 41, n. 12, p. 1617, doi. 10.1007/s40273-023-01303-5

By:

Jiao, Boshen

Publication type:

Article

De Novo Cost-Effectiveness Model Framework for Nonalcoholic Steatohepatitis—Modeling Approach and Validation.

Published in:

PharmacoEconomics, 2023, v. 41, n. 12, p. 1629, doi. 10.1007/s40273-023-01298-z

By:

Gal, Peter;
Feldmajer, Gyorgyi;
Augusto, Margarida;
Gani, Ray;
Hook, Emma;
Bullement, Ash;
Philips, Zoe;
Smith, Inger

Publication type:

Article

Capturing Value Attributes in the Economic Evaluation of Ceftazidime with Avibactam for Treating Severe Aerobic Gram-Negative Bacterial Infections in the United Kingdom.

Published in:

PharmacoEconomics, 2023, v. 41, n. 12, p. 1657, doi. 10.1007/s40273-023-01310-6

By:

Gordon, Jason;
Gheorghe, Maria;
Goldenberg, Simon;
Miller, Ryan;
Dennis, James;
Al-Taie, Amer

Publication type:

Article

Are We Capturing the Socioeconomic Burden of Rare Genetic Disease? A Scoping Review of Economic Evaluations and Cost-of-Illness Studies.

Published in:

PharmacoEconomics, 2023, v. 41, n. 12, p. 1563, doi. 10.1007/s40273-023-01308-0

By:

Marshall, Deborah A.;
Gerber, Brittany;
Lorenzetti, Diane L.;
MacDonald, Karen V.;
Bohach, Riley Jewel;
Currie, Gillian R.

Publication type:

Article